What is the regulatory status of Melanotan II (Intranasal)?

Melanotan II (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For sourcing and quality-control use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for Melanotan II (Intranasal)?

Melanotan II (Intranasal)'s evidence base sits at research level investigational. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does Melanotan II (Intranasal)'s half-life affect dosing?

Melanotan II (Intranasal) has a plasma half-life of Rapid CNS uptake; systemic ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under prn before activity or 1x daily dosing at 0.25-0.5 mg per dose explains the typical onset timeline for sourcing and quality-control endpoints.

How long until I see results from Melanotan II (Intranasal)?

Acute effects from Melanotan II (Intranasal) appear within hours of dosing for receptor-level changes. sourcing and quality-control endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ Melanotan II (Intranasal)

Melanotan II (Intranasal)

Sourcing Guide

Quality control discipline for Melanotan II (Intranasal) extends across procurement, storage, reconstitution, and use. Lyophilised vial inspection, COA cross-reference against lot, 1024 Da mass spec confirmation, and HPLC purity above 98% are the procurement layer; the storage and reconstitution layer is examined below.

Sourcing / Quality / Procurement Applications

BAC Water SourcingRegulatory SourcingVial InspectionGMP vs Research GradeMass Spectrometry Verification

Key Takeaways

Procurement lens: Melanotan II (Intranasal) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 1024 Da.
Mechanism: Same MT-II molecule via the olfactory pathway.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

Same MT-II molecule via the olfactory pathway. Faster onset of central (MC4R) effects relative to peripheral (MC1R) pigmentation. Quality control discipline for Melanotan II (Intranasal) starts with mechanism understanding: which assays detect counterfeits, which impurities matter for the intended use, and which storage conditions preserve activity. The subsections work through HPLC purity, COA evaluation, reconstitution protocol, and vendor selection.

COA evaluation and red flags

Acceptable Melanotan II (Intranasal) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Vendor tier comparison and price discipline

Three vendor tiers operate in the Melanotan II (Intranasal) market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

Reconstitution and storage protocols

Melanotan II (Intranasal) is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.

Sourcing / Quality / Procurement Applications

Mass Spectrometry Verification

Sourcing Melanotan II (Intranasal) for mass spectrometry verification use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Vendor Comparison

Pharmaceutical-grade compounded Melanotan II (Intranasal) is the lowest-risk sourcing path for vendor comparison use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Storage Protocol

For users targeting storage protocol, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

GMP vs Research Grade

Sourcing Melanotan II (Intranasal) for gmp vs research grade use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	0.25-0.5 mg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	1.25-0.5 mg	4–6 weeks initial cycle
Sourcing Guide focus	Intranasal	0.25-0.5 mg	PRN before activity or 1x daily
Maintenance phase	Intranasal	1.25-0.5 mg	Ongoing with periodic pauses

Dose timing for Melanotan II (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan II (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

Melanotan II (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan II (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Melanotan II (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan II (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Melanotan II (Intranasal) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Melanotan II (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
Melanotan II (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan II (Intranasal)'s mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved

Same as MT-II. Nasal irritation possible.

Lens-specific safety considerations for sourcing / quality / procurement use of Melanotan II (Intranasal): Same as MT-II. Nasal irritation possible. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Melanocortin receptor pharmacology

PMID 1429592

Melanotan II (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan II (Intranasal)	Cyclic α-MSH analogue (intranasal)	Rapid CNS uptake; systemic ~30 min	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Storage protocol?

Lyophilised: −20°C for 18–24 months. Reconstituted with bacteriostatic water: 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Cold-chain shipping is preferred for purchases; insulated packaging without active cooling is acceptable for shorter transit windows.

Vendor red flags?

Six markers: (1) no lot-specific COAs available, (2) HPLC purity only, no copper or stoichiometry assay where applicable, (3) no physical address or regulatory disclosure, (4) no cold-chain shipping option, (5) no refund policy for failed-QC lots, (6) therapeutic claims about research material. Multiple flags = walk away.

What should I check on a Melanotan II (Intranasal) COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching 1024 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

Visual quality inspection?

Lyophilised Melanotan II (Intranasal) should be a uniform white powder adherent to the vial wall or as a freeze-dried cake. Discoloration, residue on the rubber septum, or particulate matter in the lyophilised product are reasons to request replacement before reconstituting.

What is the standard dosing protocol for Melanotan II (Intranasal)?

Conventional Melanotan II (Intranasal) dosing is 0.25-0.5 mg prn before activity or 1x daily via intranasal. For sourcing and quality-control use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Is Melanotan II (Intranasal) safe during pregnancy or breastfeeding?

Melanotan II (Intranasal), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a Melanotan II (Intranasal) Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified Melanotan II (Intranasal) and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 1024 Da
Sequence length: 7 aa
Half-life: Rapid CNS uptake; systemic ~30 min
WADA: Not on prohibited list
FDA: Unapproved

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for Melanotan II (Intranasal)

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised